Following on from a period of exclusive evaluation announced in June 2024, Genmab has exercised its option to license an anti-glycan monoclonal antibody generated via Scancell’s proprietary GlyMab® platform.
This is the second commercial license with Genmab where Genmab has been granted worldwide exclusive rights for the development and commercialisation of novel therapeutic products for an antibody from the Scancell Glymab® platform.
Scancell is to receive an upfront payment and potential development, regulatory- and commercial milestone payments of up to a maximum of $630 million if Genmab develops and commercialises products across all defined modalities. Scancell will also receive low single-digit royalties from Genmab on net sales of all such commercialised products.
Scancell Holdings plc, the developer of novel immunotherapies for the treatment of cancer, today announces that Genmab, an international biotechnology company, has exercised its option to license a Scancell investigational anti-glycan monoclonal antibody whereby Genmab has the exclusive right to develop and commercialise the Scancell antibody in multiple novel therapeutic products. Scancell will be eligible to receive upfront and development and commercialisation milestone payments, as well as royalties on products sold.
The Scancell anti-glycan monoclonal antibody is a humanised antibody developed by Scancell, using its novel anti-cancer GlyMab® platform. This is one of five monoclonal antibodies currently in Scancell’s antibody portfolio, which provides a rich reservoir of potential products for its in-house clinical development and further deals.
Prof Lindy Durrant, Chief Scientific Officer, Scancell, commented: “This option exercise for another anti-glycan monoclonal antibody from the Glymab® platform builds on our existing relationship with Genmab. The commercial license agreement follows an exclusive evaluation period, which further validates that our Glymab® antibody platform can generate novel, differentiated, highly tumour specific antibodies for therapeutic development. We are positive about continuing to work with Genmab and providing further updates to the market on both agreements as they progress.”
This is the second commercial licence agreement Scancell has signed with Genmab following an earlier agreement signed in October 2022.